← Back to Search

Platinum-based Chemotherapy

Pembrolizumab + Chemoradiation +/- Olaparib for Stage III Lung Cancer

Phase 3
Waitlist Available
Research Sponsored by Merck Sharp & Dohme Corp.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Has no evidence of metastatic disease indicating Stage IV NSCLC
Has Stage IIIA, IIIB, or IIIC NSCLC by American Joint Committee on Cancer Version 8
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to approximately 72 months
Awards & highlights

Study Summary

This trial will compare the efficacy of three different treatments for unresectable, locally advanced NSCLC. Arm 1 will receive pembrolizumab concurrently with chemoradiation, followed by pembrolizumab with olaparib placebo. Arm 2 will receive the same treatment as Arm 1, but will take olaparib instead of the placebo. Arm 3 will receive concurrent chemoradiation therapy followed by durvalumab. The primary hypothesis is that pembrolizumab with concurrent chemoradiation and olaparib is superior to durvalumab with respect to PFS and OS.

Who is the study for?
This trial is for adults with Stage III NSCLC who haven't had previous treatments for this stage, can't have surgery to cure it, and don’t have metastatic (Stage IV) disease. They should be expected to live at least 6 months, able to perform daily activities with little or no help (ECOG 0-1), and must agree to use contraception.Check my eligibility
What is being tested?
The study tests pembrolizumab combined with chemoradiation followed by either pembrolizumab plus olaparib placebo or just olaparib versus chemoradiation followed by durvalumab. It aims to see if the first two methods are better than the third in improving survival without cancer progression.See study design
What are the potential side effects?
Possible side effects include immune system reactions affecting organs, infusion-related reactions, fatigue, nausea, blood cell changes increasing infection risk. Specifics depend on each drug combination but may also involve lung issues like pneumonitis.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My lung cancer has not spread to other parts of my body.
Select...
My lung cancer is at stage IIIA, IIIB, or IIIC.
Select...
I cannot have surgery to cure my Stage III lung cancer.
Select...
My lung cancer diagnosis was confirmed through lab tests.
Select...
My lung cancer diagnosis is confirmed by lab tests.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to approximately 72 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to approximately 72 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Overall Survival (OS)
Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
Secondary outcome measures
Change From Baseline in Chest Pain Using the EORTC QLQ-LC13 Item 10 Score
Change From Baseline in Cough Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer Module 13 (EORTC QLQ-LC13) Item 1 Score
Change From Baseline in Dyspnea Using the EORTC QLQ-C30 Item 8 Score
+13 more

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: pembrolizumab+chemoradiation→pembrolizumab+olaparib placeboExperimental Treatment8 Interventions
Participants will receive pembrolizumab 200 mg intravenously (IV) every 3 weeks (Q3W) in combination with 3 cycles of the investigator's choice of platinum doublet chemotherapy and concurrent standard thoracic radiotherapy (60 Gray (Gy) over 6 weeks) followed by pembrolizumab plus olaparib placebo twice a day (BID) for approximately 1 year.
Group II: pembrolizumab+chemoradiation→pembrolizumab+olaparibExperimental Treatment8 Interventions
Participants will receive pembrolizumab 200 mg IV Q3W in combination with 3 cycles of the investigator's choice of platinum doublet chemotherapy and concurrent standard thoracic radiotherapy (60 Gy over 6 weeks) followed by pembrolizumab plus olaparib 300 mg BID for approximately 1 year.
Group III: chemoradiation→durvalumabActive Control7 Interventions
Participants will receive 3 cycles of the investigator's choice of platinum doublet chemotherapy with concurrent standard thoracic radiotherapy (60 Gy over 6 weeks) followed by durvalumab 10 mg/kg every 2 weeks (Q2W) for approximately 1 year.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Paclitaxel
2011
Completed Phase 4
~5380
Carboplatin
2014
Completed Phase 3
~6670
Cisplatin
2013
Completed Phase 3
~1940
Etoposide
2010
Completed Phase 3
~2440
Pembrolizumab
2017
Completed Phase 2
~2010
Olaparib
2007
Completed Phase 4
~2210
Pemetrexed
2014
Completed Phase 3
~5250
Thoracic Radiotherapy
2003
Completed Phase 2
~110

Find a Location

Who is running the clinical trial?

Merck Sharp & Dohme Corp.Lead Sponsor
2,286 Previous Clinical Trials
4,581,127 Total Patients Enrolled
Merck Sharp & Dohme LLCLead Sponsor
3,901 Previous Clinical Trials
5,062,325 Total Patients Enrolled
Medical DirectorStudy DirectorMerck Sharp & Dohme LLC
2,785 Previous Clinical Trials
8,064,832 Total Patients Enrolled

Media Library

Carboplatin (Platinum-based Chemotherapy) Clinical Trial Eligibility Overview. Trial Name: NCT04380636 — Phase 3
Non-Small Cell Lung Cancer Research Study Groups: pembrolizumab+chemoradiation→pembrolizumab+olaparib placebo, pembrolizumab+chemoradiation→pembrolizumab+olaparib, chemoradiation→durvalumab
Non-Small Cell Lung Cancer Clinical Trial 2023: Carboplatin Highlights & Side Effects. Trial Name: NCT04380636 — Phase 3
Carboplatin (Platinum-based Chemotherapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04380636 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are some of the conditions that Pembrolizumab is used to manage?

"Pembrolizumab is the standard medication for melanoma. Pembrolizumab can also be used to treat neoplasm metastasis, malignant melanoma of skin, and merkel cell cancer."

Answered by AI

What other medical studies have there been with Pembrolizumab?

"Pembrolizumab was first trialed in 1997 by City of Hope Comprehensive Cancer Center. 3012 trials have completed since then and as of now, 2916 are actively ongoing. A large number clinical trials for this medication are based out of Fullerton, Indiana."

Answered by AI

What are the risks of Pembrolizumab for patients?

"Pembrolizumab has received a score of 3 for safety. This rating comes from the fact that there is some efficacy data as well as multiple rounds of safety data because it is in Phase 3 clinical trials."

Answered by AI

Would it be possible to find out how many different health care facilities are running this research project in town?

"This study is currently running at St Joseph Heritage Healthcare-Oncology ( Site 0088) in Fullerton, Franciscan St. Francis Health ( Site 0031) in Lafayette, and Rutgers Cancer Institute of New jersey ( Site 0054) in New Brunswick as well as 30 other locations."

Answered by AI

Why was this clinical trial designed, and what are its goals?

"The sponsor of the study, Merck Sharp & Dohme LLC, reports that the primary outcome will be Overall Survival (OS), which will be measured over a time frame of Up to approximately 48 months. Additionally, this trial will assess secondary outcomes including Change from Baseline in Role Functioning Using the EORTC QLQ-C30 Items 6-7 Score, Discontinuation Rate of Study Intervention Due to an Adverse Event (AE), and TTD in Cough Using the EOTRC QLQ-LC13 Item 1 Score."

Answered by AI

Who else is applying?

What state do they live in?
Maryland
How old are they?
18 - 65
What site did they apply to?
Fox Chase Cancer Center ( Site 0063)
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
~302 spots leftby Jul 2026